Rationale: Hypertension is associated with renal infiltration of activated immune cells; however, the role of renal lymphatics and immune cell exfiltration is unknown.
H ypertension affects almost 1 in 2 adults in the United
States and is the number 1 contributor to cardiovascular-renal disease. 1, 2 Of patients with hypertension, nearly 50% have salt-sensitive hypertension (SSHTN). Patients with SSHTN are at even greater risk for cardiac events and developing chronic kidney disease than patients with hypertension alone. Blacks are especially at risk because 75% of those with hypertension have SSHTN. 3 Current medications used for hypertension and SSHTN have many negative side effects, and diuretic therapy, the first-line therapy for SSHTN, can lead to altered potassium and uric acid levels. Therefore, alternative therapies for hypertension and especially SSHTN are needed.
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Renal inflammation has been identified as a partial contributor to the development of hypertension and SSHTN. Humans and animals with hypertension and SSHTN exhibit increased numbers of activated immune cells in the kidney. [4] [5] [6] [7] [8] [9] Immunosuppression reduces the number of macrophages and T cells in the body, ameliorates renal immune cell infiltration and inflammation, and prevents the development of experimental SSHTN. 4, [10] [11] [12] Because suppressing the immune systems of the ≈148 million people with hypertension in the United States is not feasible, alternative strategies to reduce renal inflammation and blood pressure are needed.
Lymphatic vessels provide a route for immune cell migration out of the interstitium to the draining lymph node. Acute inflammation initially causes lymphatic vessel dilation; however, persistent inflammation and immune system activation induce lymphangiogenesis to potentially enhance leukocyte trafficking from the tissue. Renal lymphangiogenesis is evident in chronic kidney pathologies such as diabetic nephropathy, lupus nephritis, tubulointerstitial nephritis, and IgA nephropathy. [13] [14] [15] We recently reported that renal lymphatics are increased in spontaneously hypertensive rats (SHRs) that develop renal injury but not in SHRs resistant to renal injury. 16 Whether lymphangiogenesis is merely indicative of injury is unknown. Likewise, could modulating renal lymphatics aid in limiting the inflammation associated with hypertension and specifically SSHTN?
In the current study, we used 2 different mouse models that mimic patients with SSHTN and hypertension patients with elevated levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. [17] [18] [19] [20] We also used transgenic mice that conditionally overexpress the lymphangiogenic signal VEGF-D (vascular endothelial growth factor D) only in the kidney. 21 We hypothesized that renal lymphatics are increased in both models of hypertension as a marker of inflammation. In addition, we hypothesized that enhancing renal lymphatic expansion before hypertension stimuli would limit renal immune cell accumulation and prevent the development of SSHTN and hypertension.
Methods
The data, analytic methods, and study materials that support the findings of this study are available from the corresponding authors on reasonable request.
An expanded Methods section is provided in the Online Data Supplement.
Results

SSHTN Mice Exhibit Increased Renal Lymphatic Vessel Density and Renal Immune Cell Infiltration
To test whether renal lymphatic architecture is altered in SSHTN, mice were administered nitro-l-arginine methyl ester hydrochloride (L-NAME) in their drinking water for 2 weeks, followed by a washout period of 2 weeks, and then provided a 4% high-salt diet for 3 weeks as described previously. 17 As expected, these mice were hypertensive (systolic blood pressure [SBP]: 136±2 versus 103±3 mm Hg; P<0.05; Figure 1A ). There were no differences in body weight, kidney weight/body weight, or spleen weight/body weight (Online Table III ). We then examined renal lymphatic vessel density by performing immunofluorescence on kidney sections for the lymphatic vessel markers, LYVE-1 (lymphatic vessel endothelial hyaluronan receptor 1) and podoplanin (data not shown). SSHTN mice had increased lymphatic labeling around the interlobular arteries ( Figure 1B ). Every interlobular artery per kidney section was counted, and the mean number did not differ between groups ( Figure 1C) . Next, every lumen-containing, LYVE-1 + lymphatic vessel per kidney section was counted, and the mean number of lymphatic vessels per kidney section ( Figure 1C ) and per artery ( Figure 1D ) was increased significantly in SSHTN mice. Lymphatics in the cortical region are primarily localized to the interlobular arteries. Arteries in control mice typically had 0 to 2 lymphatic vessels around them, whereas SSHTN mice had 2 to 4 lymphatic vessels around most arteries ( Figure 1E ). In support of these data, gene expression of Prox1, a lymphatic endothelial cell transcription factor, and Vegfr3, the receptor for the lymphangiogenic signal VEGF-C (vascular endothelial growth factor C) and VEGF-D, was increased significantly in SSHTN kidneys ( Figure 1F ). To determine whether the increased renal lymphatic vessel density was associated with increased immune cell infiltration, we measured gene expression of various immune cell markers in the kidney. Expression levels of the macrophage marker, Adgre1 (F4/80), and the Th1 cell marker, Tbx21, were increased significantly in SSHTN mice ( Figure 1G ). Mice given a 4% high-salt (HS) diet alone for 3 weeks did not develop hypertension (Online Figure IA ) and had no change in renal lymphatic vessel density (Online Figure IB and IC). Changes in renal gene expression of lymphatic vessel and immune cell markers associated with SSHTN were also unchanged in HS mice (Online Figure ID and IE). These results demonstrate that renal lymphatic vessel density is increased in SSHTN and is associated with renal infiltration of macrophages and Th1 cells.
Kidney-Specific Lymphatic Augmentation Prevents SSHTN Because of Reduced Macrophage and T-Cell Accumulation
To determine whether enhancing renal lymphatic vessel density could prevent SSHTN, we used mice with tet-responsive kidney-specific overexpression of murine VEGF-D ( 
Novelty and Significance
What Is Known?
• Renal inflammation is part of the cause of hypertension.
• Lymphangiogenesis is a necessary process in inflammation resolution.
What New Information Does This Article Contribute?
• Endogenous lymphatic expansion occurs in 2 murine models of hypertension.
• Genetically increasing renal lymphangiogenesis prevents hypertension.
Hypertension can be characterized as a disease of chronic renal inflammation. Inflammation and increased immune cells cause a localized expansion of lymphatic vessels through secretion of prolymphangiogenic factors in a host of preclinical and clinical studies. This lymphangiogenesis is essential for clearing fluid, chemokines, and immune cells, and, thereby, resolving inflammation. Here, endogenous renal lymphatic expansion is demonstrated in 2 murine models of hypertension. These models also demonstrate increased renal inflammation and immune cell accumulation. In an inducible model of augmented renal lymphangiogenesis, hypertension is completely prevented under these conditions. Enhanced lymphatic density reduced macrophage, dendritic cell, and T-cell populations in the kidney. This work demonstrates a novel role for renal lymphatic vessels in hypertension and kidney health and provides a significant new target for regulating or assessing blood pressure.
1 week before the 4% salt diet of the SSHTN protocol. The augmentation of renal lymphangiogenesis in KidVD + mice prevented the development of SSHTN, whereas KidVD − cagemate controls developed SSHTN (SBP: 117±4 versus 139±5 mm Hg; P<0.05; Figure 2A ). There were no differences in body weight, kidney weight/body weight, spleen weight/body weight, or heart weight/body weight (Online Table IV ). Immunofluorescence of kidney sections for LYVE-1 revealed renal lymphatic expansion in KidVD + SSHTN mice, most notably throughout the cortex ( Figure 2B ). Lymphatic structures were confirmed to also be positive for podoplanin and Prox1 (Online Figure II) . Quantification of LYVE-1 + pixels per field confirmed this significant increase in lymphatics compared with KidVD − SSHTN mice ( Figure 2C ). Increased lymphatic density was specific to the kidney with no changes in LYVE-1 staining in the heart, lung, ear skin, liver, thymus, or intestine of KidVD + mice (Online Figure III and not shown). Supporting the massive increase in renal lymphatic vessel density, KidVD + SSHTN mice had expected renal mRNA increases in the lymphatic vessel markers Lyve1 and Prox1, Vegfd, and the lymphatic-expressed immune cell trafficking chemokine Ccl21 ( Figure 2D ). The immune cell-expressed lymphatic trafficking chemokine receptor to CCL21, Ccr7, mRNA was also highly upregulated in KidVD + SSHTN kidneys compared with controls ( Figure 2E ). Renal gene expression of the macrophage marker Adgre1, which was increased significantly in SSHTN mice, was normalized in KidVD + SSHTN mice ( Figure 2E ). There was also a significant decrease in renal mRNA levels of the T-cell marker Cd3e and the Th1 cell marker Tbx21 suggesting fewer of these cells in KidVD + SSHTN kidneys ( Figure 2E ). To test whether the prevention of SSHTN in KidVD + mice was associated with decreased renal accumulation of immune cells, we performed flow cytometry analysis and found that KidVD + SSHTN kidneys had significantly decreased F4/80 + macrophages and CD3e + T cells compared with KidVD − SSHTN mice ( Figure 2F ). These results demonstrate that increasing renal lymphatic density before the high-salt diet challenge prevents the development of SSHTN in KidVD + mice, likely because of reduced renal accumulation of macrophages and Th1 cells.
L-NAME-Induced Hypertension Mice Exhibit Increased Renal Lymphatic Vessel Density and Renal Immune Cell Infiltration
To determine whether these renal lymphatic and immune cell changes occur in another model of hypertension independent of sodium, we administered L-NAME alone in the drinking water of mice for 2 weeks as described previously (L-NAMEinduced hypertension [LHTN]). 17 We confirmed the development of LHTN in these mice ( Figure 3A ). There were no differences in body weight, kidney weight/body weight, or spleen weight/body weight (Online Table V ). We labeled the kidneys for LYVE-1 and podoplanin and found that renal lymphatic vessel density was increased significantly in LHTN mice ( Figure 3B ). Similar to the SSHTN mice, the mean number of interlobular arteries per kidney section did not differ between groups ( Figure 3C ). The average number of lumencontaining, LYVE-1 + renal lymphatic vessels per kidney section and per interlobular artery were increased significantly in LHTN mice ( Figure 3C and 3D) . Most arteries in kidneys from LHTN mice had 1 to 4 lymphatic vessels around them, whereas most arteries in kidneys from control mice had 0 to 2 lymphatic vessels ( Figure 3E ). Expression of Vegfc and Vegfr3 was increased significantly in LHTN kidneys compared with controls ( Figure 3F ). Kidneys from LHTN mice also had significantly increased mRNA levels of Ccr7, Adgre1, the dendritic cell marker CD11c, and Tbx21 ( Figure 3G ). The increases associated with LHTN regressed after a 2-week washout period (LHTN-Wash) including normalization of SBP (Online Figure   IVA) , renal lymphatic vessel density (Online Figure IVB and  IVC) , lymphatic vessel markers (Online Figure IVD) , and immune cell markers (Online Figure IVE) . These data demonstrate that LHTN mice exhibit renal lymphatic expansion that is associated with increased markers of macrophages, dendritic cells, and Th1 cells.
Kidney-Specific Lymphatic Density Augmentation Prevents LHTN Because of Reduced Macrophage and Dendritic Cell Accumulation
To induce kidney-specific VEGF-D expression and initiate lymphangiogenesis, we administered doxycycline to KidVD + and KidVD − mice 1 week before L-NAME administration and continued L-NAME and doxycycline in the drinking water for 3 weeks. KidVD − LHTN mice developed LHTN within a week that remained elevated ( Figure 4A ). However, enhanced lymphatic expansion prevented the development of LHTN in KidVD + mice ( Figure 4A ). No differences were measured in body weight, kidney weight/body weight, spleen weight/ body weight, or heart weight/body weight (Online Table VI ). KidVD + LHTN kidney sections exhibited a marked increase in lymphatic vessel coverage ( Figure 4B ). Quantification of LYVE-1 + pixels per field confirmed the significant increase in cortical lymphatic vessel density ( Figure 4C ). Renal gene expression levels of lymphatic endothelial cell-related genes Lyve1, Prox1, Vegfd, Vegfr3, Ccl19, and Ccl21, as well as the immune cell-expressed chemokine receptor Ccr7, were increased significantly in KidVD + LHTN mice ( Figure 4D ). Gene expression of Adgre1, Cd11c, and Tbx21, all of which were upregulated during LHTN, was either decreased significantly or did not increase significantly in the kidneys of KidVD + LHTN mice ( Figure 4E ). KidVD + LHTN mice had significantly decreased levels of F4/80 + macrophages and CD11c + dendritic cells as determined by flow cytometry ( Figure 4F ), though unlike in SSHTN, T-cell numbers were unaffected. These results collectively demonstrate that genetic augmentation of renal lymphatic density before L-NAME administration prevents the development of LHTN, likely because of reduced accumulation of renal macrophages and dendritic cells.
Discussion
The current study supports the concept that renal immune cell accumulation plays a major role in hypertension and identifies ) and KidVD + mice administered doxycycline (DOX) in the drinking water for 4 weeks coupled with L-NAME the last 3 weeks (L-NAME-induced hypertension [LHTN] that renal lymphangiogenesis is beneficial in this pathogenesis. We demonstrate that increased renal lymphatic density occurs in 2 different models of hypertension that, if analogous to other models of inflammation-induced lymphangiogenesis, likely serves as a compensatory mechanism for removal of increased fluid and immune cells. Importantly, we also demonstrate that genetically inducing increased renal lymphatic density prevents hypertension and reduces proinflammatory renal immune cells. Renal immune cell infiltration and inflammation play a major role in SSHTN and hypertension. In effect, hypertension can be viewed as a disease of chronic, low-grade renal inflammation. Lymphangiogenesis is not only a marker of inflammation, but an important adaptation to chronic inflammation. Multiple forms of kidney injury or disease have demonstrated renal lymphangiogenesis. Conversely, blocking this process results in failed immune cell trafficking and worsened disease, and ligation of renal lymphatics induces proteinuria, tubulointerstitial fibrosis, and mesangial expansion within weeks. 22 A high-salt diet fed to control rats and SHRs induces CD68 + macrophages to produce the VEGF-C transcription factor NFAT5 (nuclear factor of activated T-cells 5) leading to dermal and cardiac lymphangiogenesis, respectively, via VEGFR-3 (vascular endothelial growth factor receptor 3). 23, 24 We reported that Fisher 344 aged rats and SHRs that develop renal injury exhibit increased renal VEGF-C, VEGFR-3, and lymphatics, and this was associated with macrophage infiltration. 16 In the current study, we detected increased renal levels of macrophages and Th1 cells in SSHTN mice and macrophages and dendritic cells in LHTN mice. Renal T cells and monocytes have been previously implicated in several hypertension models. 4, 6, 11, 25, 26 Whether these specific immune subsets (ie, CD70 T cells 17 ) are the primary inflammatory drivers likely depends on the hypertensive stimuli. We are currently exploring whether infiltrating immune cells, elevated blood pressure, and increased renal interstitial concentrations of salt or asymmetric dimethylarginine drive lymphangiogenesis in the kidney.
Renal lymphangiogenesis may be beneficial at certain times, but detrimental at others. 27 In renal transplant studies, rejection is associated with renal lymphangiogenesis and inhibition of lymphangiogenesis prolongs allograft survival. 28 Immune trafficking to the draining lymph node increases antigen presentation and propagates allograft immunity. In contrast, establishing more exit routes for immune cells may be beneficial in hypertension and SSHTN for maintaining self-tolerance. Weekly intravenous injections of a VEGF-C retrovirus into hypertensive SHRs during the last 4 weeks of a 12-week high-salt diet increased cardiac lymphatics, decreased myocardial macrophages, and reduced SBP from 197 to 189 mm Hg. 23 In addition, inhibition of dermal lymphangiogenesis worsened SSHTN. 24, 29 In the current study, VEGF-D was overexpressed specifically in the kidney to initiate renal lymphatic expansion before the hypertension stimuli. It is important to reiterate that all mice received doxycycline, which reduced SBP in some reports, to make effects specific to VEGF-D overexpression. VEGF-D-driven renal lymphangiogenesis prevented the development of both SSHTN and LHTN, and this was associated with decreased renal levels of immune cells. Studies to determine whether augmenting renal lymphatics after SSHTN/hypertension is established may be therapeutic and how inhibiting renal lymphangiogenesis impacts hypertension are underway.
In conclusion, physiological levels of renal lymphangiogenesis occur in SSHTN and hypertension but are insufficient to significantly enhance immune cell exfiltration. Kidneyspecific augmentation of lymphatic density is able to prevent the development of SSHTN and hypertension in mice. The current study suggests that renal lymphatic density may be predictive in identifying individuals at risk of developing SSHTN/hypertension and identifies a potential new therapeutic strategy for patients incapable of renal lymphatic expansion in response to hypertension stimuli.
